Boston Scientific Corporation (VIE:BSXC)
Austria · Delayed Price · Currency is EUR | Market Cap | 78.80B -39.2% |
| Revenue (ttm) | 17.88B +17.4% |
| Net Income | 3.09B +75.4% |
| EPS | 2.07 +74.4% |
| Shares Out | n/a |
| PE Ratio | 25.48 |
| Forward PE | 17.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77 |
| Average Volume | 559 |
| Open | 52.93 |
| Previous Close | 53.79 |
| Day's Range | 51.97 - 53.22 |
| 52-Week Range | 50.73 - 94.80 |
| Beta | n/a |
| RSI | 41.42 |
| Earnings Date | Apr 22, 2026 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatogra... [Read more]
Financial Performance
In 2025, Boston Scientific's revenue was $20.07 billion, an increase of 19.87% compared to the previous year's $16.75 billion. Earnings were $2.90 billion, an increase of 56.40%.
Financial numbers in USD Financial StatementsNews
Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
Positive data for FARAPULSE™ Pulsed Field Ablation and WATCHMAN™ LAAC Devices underscore therapy safety and effectiveness in late-breaking clinical trial sessions MARLBOROUGH, Mass. and CHICAGO, Apri...
5 Early Q1 Earnings Winners Beating Expectations
Believe it or not, earnings season is once again upon us, and some crucial large-cap stocks like Tesla, American Express, and Intel already reported results this week.
Boston Scientific Analysts Slash Their Forecasts After Q1 Earnings
Boston Scientific Corporation (NYSE:BSX) reported upbeat earnings for the first quarter on Wednesday.
Boston Scientific Earnings Call Transcript: Q1 2026
Q1 2026 delivered 9.4% organic sales growth and 6% adjusted EPS growth, but full-year guidance was reduced due to headwinds in EP, WATCHMAN, and Urology. Management expects improvement in the second half, with key product launches and commercial investments supporting future growth.
Boston Scientific cuts 2026 profit forecast, trims revenue growth view
Medical device maker Boston Scientific cut its annual profit forecast on Wednesday, overshadowing a first-quarter earnings and revenue beat, while its shares were little changed after earlier volatil...
Boston Scientific Net Grows Sharply
Boston Scientific said its first-quarter net income roughly doubled as demand continued to grow worldwide for its stents, catheters and other cardiology devices.
Boston Scientific announces results for first quarter 2026
MARLBOROUGH, Mass., April 22, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported ...
Top Wall Street Forecasters Revamp Boston Scientific Expectations Ahead Of Q1 Earnings
Boston Scientific Corporation (NYSE:BSX) will release earnings for its first quarter before the opening bell on Wednesday, April 22.
BOSTON SCIENTIFIC CORPORATION (BSX) DEADLINE ALERT Bernstein Liebhard LLP Reminds Boston Scientific Corporation Investors of Upcoming Deadline
Boston Scientific Shareholders Between July 23, 2025 and February 3, 2026 - Contact Bernstein Liebhard For More Information Regarding Shareholder Lawsuit
BSX Stockholders Have Rights – If You Lost Money Investing in Boston Scientific Corporation Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Boston Scientific Corporatio...
Boston Scientific Drops Despite Encouraging Trial Readouts
The CHAMPION-AF study results shared on Saturday highlighted the WATCHMAN FLX device's efficacy compared to traditional blood thinners as a first-line option for stroke risk reduction in a broad popul...
Boston Scientific announces conference call discussing first quarter 2026 results
MARLBOROUGH, Mass., March 30, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter...
Boston Scientific Transcript: American College of Cardiology 75th Annual Scientific Session and Expo
HI-PEITHO and CHAMPION-AF trials showed significant clinical and safety benefits for device-based therapies in pulmonary embolism and atrial fibrillation, supporting label expansion and market growth. The company targets a 20% growth rate, with regulatory submissions and new device launches planned.
CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla...
HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism
Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. antico...
BSX Lawsuit Alleges Claims Executives Misrepresented U.S. Electrophysiology Volumes - BOSTON SCIENTIFIC CORPORATION Investors Face Losses Following Claims Executives Misrepresented U.S. Electrophysiology Volumes: SueWallSt
Alert: Claims Focus on Alleged Misrepresentations About U.S. Electrophysiology Procedure Growth NEW YORK, March 12, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Boston Scientific C...
BSX Investors Have Opportunity to Join Boston Scientific Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $BSX--BSX Investors Have Opportunity to Join Boston Scientific Corporation Fraud Investigation with the Schall Law Firm.
BOSTON SCIENTIFIC CORPORATION (BSX) INVESTOR ALERT Investors With Large Losses in Boston Scientific Corporation Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Boston Scientific Shareholders Between July 23, 2025 and February 3, 2026 - Contact Bernstein Liebhard For More Information Regarding Shareholder Lawsuit
Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology
MARLBOROUGH, Mass., March 6, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host an investor event and live webcast on Saturday, March 28, 2026, at 6:30 p.m.
Boston Scientific Corporation Investigated by the Portnoy Law Firm
LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Boston Scientific Corporation, (“Boston Scientific" or the "Company") (NYSE:BSX) investors that the firm has initiated an i...
Boston Scientific Transcript: TD Cowen 46th Annual Health Care Conference
Management reaffirmed double-digit growth and margin improvement targets, driven by strong execution, innovation in EP and PFA, and portfolio expansion through acquisitions like Penumbra. WATCHMAN's upcoming CHAMPION-AF trial could significantly expand its market.
Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended Decembe...
Boston Scientific elects Cathy Smith and Christophe Weber to Board of Directors
MARLBOROUGH, Mass., Feb. 23, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Cathy Smith and Christophe Weber to its Board of Directors, effective Februa...